Congressionally Directed Medical Research Programs (CDMRP)
The PRMRP Technology/Therapeutic Development Award (TTDA) is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, in at least one of the Congressionally directed FY18 PRMRP Topic Areas. Products in development should be responsive to the healthcare needs of military Service members, Veterans, and/or beneficiaries.
The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product. A “Knowledge Product” is a non-materiel product that addresses an identified need in a Topic Area, is based on current evidence and research, aims to transition into medical practice, training, tools, or to support materiel solutions (systems to develop, acquire, provide, and sustain medical solutions and capabilities), and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes. The Principal Investigator (PI) must provide a transition plan (including potential funding and resources) showing how the product will progress to the next level of development (e.g., clinical trials, delivery to the military or civilian market) after the completion of the PRMRP award. PIs are encouraged to develop relationships with industry and/or other funding agencies to facilitate moving the product into the next phase of development.
The vision of the FY18 PRMRP is to improve the health and well-being of all military Service members, Veterans, and beneficiaries. The PRMRP challenges the scientific and clinical communities to address at least one of the FY18 PRMRP Topic Areas with original ideas that foster new directions along the entire spectrum of research and clinical care. The program seeks applications in laboratory, clinical, behavioral, epidemiologic, and other areas of research to advance knowledge in disease etiology, improve prevention, detection, diagnosis, treatment, and quality of life for those affected by a relevant disease or condition, and to develop and validate clinical care or public health guidelines.
Key Mechanism Elements
- Supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, or quality of life in the Topic Area(s) of interest
- Product-oriented (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item, such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product
- Clinical trials will not be funded
- Preproposal (Letter of Intent) submission is required; application submission is by invitation only
Assistant Professor level or above (or equivalent).
Maximum Project Value
Maximum funding of $3 million U.S.
10% as per program guidelines.
Maximum period of performance is three years.
If College-level review is required, your College will communicate its earlier internal deadlines.
Pre-Application (LOI) due to sponsor through online portal.
If invited to full-proposal, please notify Kristin Gibson by email. The full proposal and OR-5 are due to firstname.lastname@example.org two weeks in advance of the external deadline to allow for review and compilation of supporting documents.
Application due to sponsor through online portal. Office of Research Services staff to submit on behalf of the PI.
How to Apply
Grant.gov Funding Opportunity Number: W81XWH18PRMRPTTDA